Free tool
Rare disease stocks
We cover 41 companies grouped under the Rare disease theme. The median market value in the group is $575.28M. Across the group, the median move over the past trading day is +0.74%. 85% of the 40 with a 200-day average trade above it. Price change over the past year runs from −24.8% to +343.2% across the middle 80 percent of the group, with a median of +46.6%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
41 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $112.52B | Large cap | +42.39% |
| A1RG34.SA | argenx SE | $63.17B | Large cap | +44.49% |
| CORT | Corcept Therapeutics Incorporated | $13.36B | Large cap | +79.56% |
| B1MR34.SA | BioMarin Pharmaceutical Inc. | $12.54B | Large cap | +6.36% |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $9.93B | Mid cap | +12.68% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +182.02% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.17B | Mid cap | +340.71% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +52.72% |
| ETON | Eton Pharmaceuticals, Inc. | $1.80B | Small cap | +268.93% |
| FBRX | Forte Biosciences, Inc. | $1.63B | Small cap | +580.25% |
| KALV | KalVista Pharmaceuticals Inc | $1.44B | Small cap | +107.85% |
| OMER | Omeros Corporation | $1.40B | Small cap | +343.22% |
| CLYM | Climb Bio Inc | $1.02B | Small cap | +619.35% |
| 0QNA.L | Basilea Pharmaceutica AG | $762.45M | Small cap | +38.97% |
| ASMB | Assembly Biosciences, Inc. | $718.32M | Small cap | +32.72% |
| VALN | Valneva SE | $642.90M | Small cap | −28.10% |
| AQST | Aquestive Therapeutics, Inc. | $602.46M | Small cap | +31.61% |
| 0KBU.L | Omeros Corporation | $575.28M | Small cap | +341.05% |
| KMDA | Kamada Ltd. Ordinary Shares | $497.90M | Small cap | +26.12% |
| PRQR | ProQR Therapeutics N.V. | $335.86M | Small cap | +5.78% |
| IFRX | InflaRx N.V. | $302.10M | Small cap | +167.10% |
| 0OB3.L | Valneva SE | $270.41M | Small cap | −24.84% |
| XUP.DE | Genfit S.A. | $258.22M | Small cap | +166.82% |
| PEPG | PepGen Inc. | $237.21M | Small cap | +161.45% |
| CRDL | Cardiol Therapeutics Inc. | $233.65M | Small cap | +75.44% |
| CRDL.TO | Cardiol Therapeutics Inc. | $233.07M | Small cap | +72.50% |
| SPRB | Spruce Biosciences, Inc. | $182.21M | Small cap | +697.48% |
| 0H8T.L | Aclaris Therapeutics, Inc. | $122.82M | Small cap | +265.21% |
| PAR.AX | Paradigm Biopharmaceuticals Limited | $96.60M | Micro cap | −22.41% |
| 0IIM.L | Esperion Therapeutics, Inc. | $61.56M | Micro cap | +46.64% |
| NSRX | Nasus Pharma Ltd. | $48.01M | Micro cap | −48.69% |
| 4884.T | Kringle Pharma, Inc. | $22.99M | Micro cap | −7.41% |
| VYNE | VYNE Therapeutics Inc | $19.07M | Micro cap | +8687.69% |
| CMMB | Chemomab Therapeutics Ltd. | $16.85M | Micro cap | −33.91% |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.48M | Micro cap | +205.34% |
| 0A8E.L | Xeris Biopharma Holdings, Inc. | — | — | +10.09% |
| 0A8U.L | Synlogic, Inc. | — | — | −15.17% |
| 0ABW.L | Egetis Therapeutics AB (publ) | — | — | +49.12% |
| 0D1W.L | Biophytis S.A. | — | — | −53.43% |
| 0K1R.L | Viridian Therapeutics, Inc. | — | — | +31.82% |
| BSLN.SW | Basilea Pharmaceutica AG | — | — | +38.40% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.